LivingGLP1
Study S000073

A Randomized, 24 Weeks, Active-controlled, Open-label, 2-arm Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to IDegAsp in Chinese Type 2 Diabetes Mellitus Participants Insufficiently Controlled With Oral Antidiabetic Drug(s)

Included trial: extracted dataClinicalTrials.gov recordStudy Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration
NCT05413369
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
NONE
Status
COMPLETED
Enrollment
582
Start
2022-07-07
Primary completion
2023-10-20
Lead sponsor
Sanofi
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:Insulin glargine/Lixisenatide; DRUG:IDegAsp; DRUG:Metformin; DRUG:SGLT2 inhibitor
Results posted
TRUE
Individual participant data sharing
YES
Secondary identifiers
REGISTRY:U1111-1267-2772

Registered primary outcomes

  • Change in HbA1c From Baseline to Week 24: Non-Inferiority Analysis [Baseline, Week 24]

Linked records (6)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0005580Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: a BRAVO model-based evaluation.
Qin J, Frontiers in public health
2026Nonrandomized studyPMID 42273622DOIcites ClinicalTrials.gov:NCT05413369
R00457331748-P: IGlarLixi Improves PPG and DTIR in Asian People with T2D (PwT2D): Post Hoc Pooled Analysis of Ph3 Studies
WENJIAN LIN, Diabetes
2026OtherDOIcites ClinicalTrials.gov:NCT05413369
R004568023-PUB: Efficacy and Safety of IGlarLixi vs. IDegAsp by Baseline HbA1c in Chinese People with T2D—Post Hoc Analyses of the SoliD Study
Hongyu Kuang, Diabetes
2025OtherDOIcites ClinicalTrials.gov:NCT05413369
R00518441988-LB: Impact of Time of Injection Comparing iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes—Exploratory Analysis of the SoliD Study
Xin Li, Diabetes
2025Other trialDOIcites ClinicalTrials.gov:NCT05413369
R0013589The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
Liu M, Diabetes, obesity & metabolism
2024Randomized trialPMID 38922731DOIcites ClinicalTrials.gov:NCT05413369
R00396831869-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes (T2D) Suboptimally Controlled with Oral Antidiabetic Drug(s) (OAD)—The SoliD Randomized Controlled Trial
MING LIU, Diabetes
2024Randomized trialDOIcites ClinicalTrials.gov:NCT05413369